Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) have received an average recommendation of “Buy” from the nineteen ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, sixteen have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $62.1429.

Several research firms recently commented on DFTX. Canaccord Genuity Group set a $64.00 target price on Definium Therapeutics and gave the stock a “buy” rating in a report on Thursday. Stifel Nicolaus boosted their price target on Definium Therapeutics from $30.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Needham & Company LLC upped their price objective on Definium Therapeutics from $50.00 to $66.00 and gave the stock a “buy” rating in a research report on Wednesday. Royal Bank Of Canada raised their price objective on shares of Definium Therapeutics from $57.00 to $66.00 and gave the stock an “outperform” rating in a research note on Thursday. Finally, JonesTrading lifted their target price on shares of Definium Therapeutics from $74.00 to $90.00 and gave the company a “buy” rating in a report on Thursday.

Definium Therapeutics News Summary

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium reported that its Phase 3 VOYAGE study of DT120 ODT in generalized anxiety disorder achieved its primary goals. The treatment produced a 5.4-point improvement on the HAM-A anxiety scale versus placebo, strengthening the case for DT120’s potential efficacy and supporting future regulatory and commercial plans. Definium Says DT120 Phase 3 GAD Study Shows 5.4-Point HAM-A Benefit vs Placebo
• Positive Sentiment: The positive clinical readout has increased confidence in additional DT120 trials and potentially supports the drug’s use across more than one indication. Investors are also watching for a further catalyst expected in September 2026. Definium Therapeutics Hits Phase 3 GAD Goals For DT120 ODT
• Positive Sentiment: Analysts raised their targets following the data: JonesTrading increased its target to $90 from $74 and maintained a Buy rating; Robert W. Baird raised its target to $75 from $57; Wells Fargo lifted its target to $72 from $68; and RBC raised its target to $66 from $57 while assigning an Outperform rating. These revisions indicate substantial perceived upside, although targets are not guarantees. Analyst price-target updates
• Positive Sentiment: Needham reportedly expects DFTX shares to rise, while recent analyst commentary broadly reflects optimism about DT120’s development prospects. Needham analyst outlook
• Neutral Sentiment: Near-term trading may remain volatile as investors assess the Phase 3 results, upcoming milestones, and expectations for third-quarter earnings. HC Wainwright Q3 earnings estimate
• Negative Sentiment: DFTX remains an unprofitable biotechnology company, and its latest reported quarter missed consensus EPS estimates. The stock’s large recent rally and elevated volatility could also encourage profit-taking despite the favorable trial news.

Definium Therapeutics Price Performance

Shares of DFTX opened at $42.63 on Friday. The business’s 50-day moving average is $39.83 and its two-hundred day moving average is $26.82. The company has a market capitalization of $5.73 billion, a P/E ratio of -12.43 and a beta of 2.23. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95. Definium Therapeutics has a fifty-two week low of $8.70 and a fifty-two week high of $49.70.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Research analysts predict that Definium Therapeutics will post -2.81 earnings per share for the current year.

Insider Activity

In related news, CFO Brandi Roberts sold 3,013 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $135,675.39. Following the sale, the chief financial officer owned 209,487 shares in the company, valued at approximately $9,433,199.61. This trade represents a 1.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mark Sullivan sold 13,008 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $585,750.24. Following the sale, the insider owned 320,571 shares in the company, valued at approximately $14,435,312.13. This represents a 3.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 48,096 shares of company stock valued at $2,165,763. 2.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Definium Therapeutics

Institutional investors have recently modified their holdings of the business. Royal Bank of Canada raised its holdings in Definium Therapeutics by 10.4% in the 1st quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock worth $382,000 after purchasing an additional 6,148 shares during the period. Creative Planning boosted its position in Definium Therapeutics by 2.6% during the second quarter. Creative Planning now owns 66,097 shares of the company’s stock worth $429,000 after purchasing an additional 1,655 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Definium Therapeutics by 5.1% in the second quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company’s stock valued at $315,000 after purchasing an additional 2,342 shares during the period. Rhumbline Advisers grew its holdings in Definium Therapeutics by 6.3% in the second quarter. Rhumbline Advisers now owns 115,296 shares of the company’s stock valued at $748,000 after purchasing an additional 6,839 shares during the period. Finally, Russell Investments Group Ltd. grew its holdings in Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after purchasing an additional 2,003 shares during the period. 27.91% of the stock is currently owned by institutional investors and hedge funds.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.